[at Motley Fool] – Like many of its peers, drugmaker Eli Lilly has faced some severe patent-cliff issues. Can it find the same success as Pfizer and Merck in addressing those issues and boost earnings?
Read more on this.
Pfizer Inc. (PFE), with a current value of $201.69B, opened this morning at $30.47.
Looking at today’s market, PFE one day range is $30.35 to $30.64 with a trailing 52-week range being $23.55 to $31.15.
Priced at 14.13x this year’s forecasted earnings, PFE shares are relatively expensive compared to the industry’s 7.41x forward p/e ratio.
And for dividend hunters, the company pays shareholders $0.96 per share annually in dividends, yielding 3.10%.
Consensus earnings for the current quarter by the 16 sell-side analysts covering the stock is an estimate of $0.56 per share, which would be $0.03 better than the year-ago quarter and a $0.00 sequential decrease. In looking at the bigger picture, the full-year EPS estimate of $2.16 would be a $0.03 setback when compared to the previous year’s annual results.
The quarterly earnings estimate is predicated on a consensus revenue forecast of $12.70 Billion. If reported, that would be a 9.16% decrease over the year-ago quarter.
Standpoint Research downgraded PFE from Hold to Sell (Jul 2, 2013).
Previously, MKM Partners downgraded PFE from Buy to Neutral.
Investors should keep in mind is that the average price target is $31.91, which is 4.73% above where the stock opened this morning.
Pfizer Inc. (NYSE:PFE), a biopharmaceutical company, discovers, develops, manufactures and sells medicines for people and animals worldwide. Its Primary Care segment offers human prescription pharmaceutical products primarily prescribed by primary-care physicians.
Tag Helper ~ Stock Code: PFE | Common Company name: Pfizer | Full Company name: Pfizer Inc. (NYSE:PFE) .